EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Phase II trial of imatinib mesylate in patients with PDGFRA/B ‐negative hypereosinophilic syndrome

Dong Hyun Kim iD, Seokhyeon Kim, Seonyang Park, Ja Min Byun iD, Junshik Hong iD, Dong-Yeop Shin iD, Inho Kim iD, Soo Mee Bang iD, Jeong-Ok Lee, Ji Yun Lee, Sang-A Kim iD, Ki Hwan Kim und 4 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19828 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Dong Hyun Kim und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Imatinib Mesylate, Hypereosinophilic Syndrome, Receptor, Platelet-Derived Growth Factor alpha. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea (NRF), Korean Government (Ministry of Science, ICT, and Future Planning).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of imatinib in PDGFRA/B ‐negative hypereosinophilic syndromes (HES) is controversial because of the heterogeneity of HES and the scarcity of prospective studies. We conducted a phase II clinical trial to evaluate the efficacy of imatinib in PDGFRA/B ‐negative HES. Thirty‐two patients were treated with imatinib (100–400 mg daily), and the molecular basis of their response was identified using whole‐exome sequencing (WES) and whole‐transcriptome sequencing (WTS). The haematological response rate was 46.9%, with a complete haematological response (CHR) rate of 18.8%. The median time to response was 1.5 months. Among the six patients who achieved CHR, five maintained it until the 24th cycle of imatinib and one lost response after 20 months. The median progression‐free survival was 4.3 months. WES and WTS were conducted for 11 patients. The number of non‐silent mutations did not differ between responders and non‐responders. Nine differentially expressed genes, including SNORD15A , were downregulated in responders. STAT5B :: RARA , PAK2 :: PIGX , and FIP1L1 :: CHIC2 fusions were identified in patients with sustained responses, and RNF130 :: BRAF and WNK1 :: KDM5A fusions were identified in non‐responders. Imatinib, along with an appropriate biomarker, could be a promising option for PDGFRA/B ‐negative HES.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateHypereosinophilic SyndromeReceptor, Platelet-Derived Growth Factor alphaHumansMaleFemaleMiddle AgedAdultAgedReceptor, Platelet-Derived Growth Factor betaExome SequencingMutationTreatment Outcome

Stichwörter der Autor:innen

PDGFRA/B‐negativehypereosinophilic syndromeimatinibwhole‐exome sequencingwhole‐transcriptome sequencing

Substanzen

Imatinib MesylateReceptor, Platelet-Derived Growth Factor alphaReceptor, Platelet-Derived Growth Factor betaPDGFRB protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
  • Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, Korea.
  • Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
  • Cancer for Medical Innovation, Seoul National University Hospital, Seoul, Korea.

ORCID-Profile: Dong Hyun Kim, Ja Min Byun, Junshik Hong, Dong-Yeop Shin, Inho Kim, Soo Mee Bang, Sang-A Kim, Youngil Koh, Sung-Soo Yoon

Förderung

  • National Research Foundation of Korea (NRF)
  • Korean Government (Ministry of Science, ICT, and Future Planning)

Zitieren

APA

Kim, D. H., Kim, S., Park, S., Byun, J. M., Hong, J., Shin, D. Y., Kim, I., Bang, S. M., Lee, J. O., Lee, J. Y., Kim, S. A., Kim, K. H., Chung, Y. J., Jung, S. H., Koh, Y., & Yoon, S. S. (2024). Phase II trial of imatinib mesylate in patients with PDGFRA/B ‐negative hypereosinophilic syndrome. British Journal of Haematology. https://doi.org/10.1111/bjh.19828

Vancouver

Kim DH, Kim S, Park S, Byun JM, Hong J, Shin DY, et al. Phase II trial of imatinib mesylate in patients with PDGFRA/B ‐negative hypereosinophilic syndrome. British Journal of Haematology. 2024. doi:10.1111/bjh.19828

BibTeX
@article{Kim2024,
  author = {Kim, Dong Hyun and Kim, Seokhyeon and Park, Seonyang and Byun, Ja Min and Hong, Junshik and Shin, Dong-Yeop and Kim, Inho and Bang, Soo Mee and Lee, Jeong-Ok and Lee, Ji Yun and Kim, Sang-A and Kim, Ki Hwan and Chung, Yeun-Jun and Jung, Seung-Hyun and Koh, Youngil and Yoon, Sung-Soo},
  title = {Phase II trial of imatinib mesylate in patients with PDGFRA/B ‐negative hypereosinophilic syndrome},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19828}
}
Kostenlos starten →